Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Tropical Diseases, Travel Medicine and Vaccines|February 1, 2022
Characteristics and potential quality indicators for evaluating pre-travel consultations in Japan hospitals: the Japan Pretravel consultation registry (J-PRECOR)Kei Yamamoto, Yusuke Asai, Issaku Nakatani, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|August 20, 2023
Characteristics of preventive intervention acceptance for international travel among clients aged 60 years and older from a Japanese multicenter pretravel consultation registryKei Yamamoto, Yusuke Asai, Hidenori Nakagawa, et al.
Microbiology Spectrum|April 27, 2026
Difficult-to-treat resistance (DTR), treatment, and outcomes of carbapenem-resistant Enterobacterales infections in the setting of IMP-type carbapenemase predominance in JapanKoji Ohyama, Kohei Uemura, Yasufumi Matsumura, et al.
Microbial Genomics|July 7, 2026
Genomic analysis of intrahospital transmission of carbapenem-resistant Gram-negative bacteria: a multicentre study in JapanYasufumi Matsumura, Yohei Doi, Kayoko Hayakawa, et al.
Open Forum Infectious Diseases|October 17, 2025
Features of Carbapenem-resistant Gram-negative Bacterial Infections in Japan Based on the Setting of OnsetYuya Kawamoto, Yusuke Asai, Aki Sakurai, et al.
Jac-Antimicrobial Resistance|March 7, 2025
Molecular epidemiology and patient outcome of carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii in Japan: a multicenter study from MultiDrug-Resistant organisms clinical research networkSho Saito, Aki Sakurai, Yasufumi Matsumura, et al.
Vaccine|April 3, 2026
Effectiveness of JN.1-adapted COVID-19 vaccine against medically attended SARS-CoV-2 infection and COVID-19 hospitalization in adults in Japan, from October 2024 to April 2025: VERSUSHaruka Maeda, Nobuo Saito, Ataru Igarashi, et al.
Expert Review of Vaccines|January 30, 2024
Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)Haruka Maeda, Nobuo Saito, Ataru Igarashi, et al.
Pageof 5